Showing 8621-8630 of 9366 results for "".
- Skyrizi Performs Well in Phase 3 Studies of PsAhttps://practicaldermatology.com/news/skyrizi-performs-well-in-phase-3-studies-of-psa/2460647/Two Phase 3 studies of Risankizumab (Skyrizi) show improvements in disease activity across joint and skin symptoms in patients with psoriatic arthritis. KEEPsAKE-1 and KEEPsAKE-2 found that significantly more patients treated with risankizumab (150 mg) achieved the primary end
- Revlon Names Martine Williamson As Chief Marketing Officerhttps://practicaldermatology.com/news/revlon-names-martine-williamson-as-its-chief-marketing-officer/2460625/Martine Williamson is Revlon’s new Chief Marketing Officer. In this role, Williamson will be central to creating and spearheading global strategic plans across the brand portfolio and overseeing Revlon’s overall brand equity and architecture. Williamson officially join
- IPC Weighs In On COVID-19 Vaccine Safety and Psoriasishttps://practicaldermatology.com/news/ipc-weighs-in-on-covid-19-vaccine-safety-and-psoriasis/2460623/The International Psoriasis Council (IPC) released guidance on the potential impact of psoriasis therapy, particularly systemic therapy, on a SARS-CoV-2 vaccine. The principal considerations for SARS-CoV-2 vaccines are the same as for any vaccine, the IPC notes. Avo
- Telemedicine Slashes Dermatology Consult Time from 84 Days to 5 Hourshttps://practicaldermatology.com/news/telemedicine-slashes-dermatology-consult-time-from-84-days-to-5-hours/2460609/When patients’ primary care doctors were able to photograph areas of concern and share them with dermatologists, the response time for a consultation dropped from almost 84 days to under five hours, finds a new study from researchers in the Perelman School of Medicine at the Unive
- Study: “Baby Botox” Boosts Skin Texture, Shrinks Poreshttps://practicaldermatology.com/news/study-baby-botox-boosts-skin-texture-shrinks-pores/2460603/Using many tiny doses of botulinum toxin injected in a grid pattern just under the surface of the facial skin may improve skin texture and roughness, according to a
- Tremfya Reduces Fatigue in PsAhttps://practicaldermatology.com/news/tremfya-reduces-fatigue-in-psa/2460602/The IL-23 blocker Tremfya (guselkumab) improves fatigue in adult patients with active psoriatic arthritis (PsA) and this response is maintained through 52 weeks of active treatment, according to data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2. Tremfya improved
- Cosentyx Shows Early Synovitis Reduction in PsAhttps://practicaldermatology.com/news/cosentyx-shows-early-synovitis-reduction-in-psa/2460600/Cosentyx (secukinumab) showed early reduction of synovitis in psoriatic arthritis (PsA), according to the Phase IIIb ULTIMATE trial which will be presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting. Specifically, a significant reduction of synovitis&n
- Ilumya Shows 5-Year Sustained Efficacy and Safety in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-shows-5-year-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis/2460596/Patients with moderate-to-severe plaque psoriasis who continued to receive Ilumya (tildrakizumab-asmn) through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety signals, according to Phase 3 data from the combined reSURFACE 1 and reSURFACE 2
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi
- Soliton Names New President and CEOhttps://practicaldermatology.com/news/soliton-names-new-president-and-ceo/2460593/Brad A. Hauser is the new President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's April 2017